Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$481.15 USD

481.15
208,477

-1.12 (-0.23%)

Updated Oct 4, 2024 11:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.

Here's Why You Should Hold on to Abiomed (ABMD) Stock Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Should Value Investors Buy McKesson (MCK) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Merit Medical's (MMSI) New Launch to Boost Patient Outcome

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its radial portfolio is expected to significantly optimize hemostasis for radial artery procedures.

Nalak Das headshot

Buy These 5 Corporate Giants Flying High in Disappointing 2022

by Nalak Das

We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.

SmileDirectClub (SDC) Q3 Earnings Beat, Gross Margin Dips

by Zacks Equity Research

Challenges to consumer spending and sustained high inflation continue to impact SmileDirectClub's (SDC) overall expected demand for 2022.

Henry Schein's (HSIC) New Deal to Improve Patient Outcome

by Zacks Equity Research

Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.

Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?

by Zacks Equity Research

Sector ETF report for FXG

Is SPDR Russell 1000 Momentum Focus ETF (ONEO) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEO

What's in the Cards for Medtronic (MDT) in Q2 Earnings?

by Zacks Equity Research

Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.

Neogen's (NEOG) Synergize Disinfectant Now Widely Available

by Zacks Equity Research

Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.

Should SPDR Russell 1000 Momentum Focus ETF (ONEO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEO

NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut

by Zacks Equity Research

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.

Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Cardinal Health's (CAH) Velocare to Enhance at-Home Care

by Zacks Equity Research

Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.

3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.

PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health

by Zacks Equity Research

PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.

Phibro (PAHC) Q1 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Phibro's (PAHC) growing uptake of MFAs, dairy products and vaccines buoys optimism.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Patterson Companies' (PDCO) New Buyout to Expand Product Suite

by Zacks Equity Research

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.

Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment

by Zacks Equity Research

Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: JPMorgan, Berkshire Hathaway, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.